File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Second malignant neoplasms after treatment of non-Hodgkin’s lymphoma—a retrospective multinational study of 189 children and adolescents

TitleSecond malignant neoplasms after treatment of non-Hodgkin’s lymphoma—a retrospective multinational study of 189 children and adolescents
Authors
Issue Date2021
PublisherSpringer Nature [academic journals on nature.com]. The Journal's web site is located at http://www.nature.com/leu
Citation
Leukemia, 2021, v. 35 n. 2, p. 534-549 How to Cite?
AbstractData on the spectrum of second malignant neoplasms (SMNs) after primary childhood non-Hodgkin’s lymphoma (NHL) are scarce. One-hundred-and-eighty-nine NHL patients diagnosed in a 30 years period of 1980–2010 developing an SMN were retrieved from 19 members of the European Intergroup for Childhood NHL and/or the international Berlin-Frankfurt-Münster Study Group. Five subgroups of SMNs were identified: (1) myeloid neoplasms (n = 43; 23%), (2) lymphoid neoplasms (n = 51; 27%), (3) carcinomas (n = 48; 25%), (4) central nervous system (CNS) tumors (n = 19; 10%), and (5) “other” SMNs (n = 28; 15%). In 37 patients (20%) preexisting disorders were reported with 90% having any kind of cancer predisposition syndrome (CPS). For the 189 primary NHL patients, 5-year overall survival (OS) after diagnosis of an SMN was 56 ± 4%, being worst for patients with preexisting disorders at 28 ± 8%. Five-year OS rates were 38 ± 8%, 59 ± 7%, 79 ± 8%, 34 ± 12%, and 62 ± 11%, respectively, for patients with myeloid and lymphoid neoplasms, carcinomas, CNS tumors, and “other” SMNs (p < 0.0001). Patients with SMNs after childhood NHL having a reported CPS, mostly mismatch repair disorders, carried a very poor prognosis. Moreover, although outcome was favorable in some subtypes of SMNs after childhood NHL (carcinomas, lymphoid neoplasms), other SMNs such as myeloid neoplasms and CNS tumors had a dismal prognosis.
Persistent Identifierhttp://hdl.handle.net/10722/291113
ISSN
2023 Impact Factor: 12.8
2023 SCImago Journal Rankings: 3.662
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorAttarbaschi, A-
dc.contributor.authorCarraro, E-
dc.contributor.authorRonceray, L-
dc.contributor.authorAndrés, M-
dc.contributor.authorBarzilai-Birenboim, S-
dc.contributor.authorBomken, S-
dc.contributor.authorBrugières, L-
dc.contributor.authorBurkhardt, B-
dc.contributor.authorCeppi, F-
dc.contributor.authorChiang, AKS-
dc.contributor.authorCsoka, M-
dc.contributor.authorFedorova, A-
dc.contributor.authorJazbec, J-
dc.contributor.authorKabickova, E-
dc.contributor.authorLoeffen, J-
dc.contributor.authorMellgren, K-
dc.contributor.authorMiakova, N-
dc.contributor.authorMoser, O-
dc.contributor.authorOsumi, T-
dc.contributor.authorPourtsidis, A-
dc.contributor.authorRigaud, C-
dc.contributor.authorUyttebroeck, A-
dc.contributor.authorWoessmann, W-
dc.contributor.authorPillon, M-
dc.contributor.authorOn behalf of the European Intergroup for Childhood Non-Hodgkin’s Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group-
dc.date.accessioned2020-11-04T01:39:46Z-
dc.date.available2020-11-04T01:39:46Z-
dc.date.issued2021-
dc.identifier.citationLeukemia, 2021, v. 35 n. 2, p. 534-549-
dc.identifier.issn0887-6924-
dc.identifier.urihttp://hdl.handle.net/10722/291113-
dc.description.abstractData on the spectrum of second malignant neoplasms (SMNs) after primary childhood non-Hodgkin’s lymphoma (NHL) are scarce. One-hundred-and-eighty-nine NHL patients diagnosed in a 30 years period of 1980–2010 developing an SMN were retrieved from 19 members of the European Intergroup for Childhood NHL and/or the international Berlin-Frankfurt-Münster Study Group. Five subgroups of SMNs were identified: (1) myeloid neoplasms (n = 43; 23%), (2) lymphoid neoplasms (n = 51; 27%), (3) carcinomas (n = 48; 25%), (4) central nervous system (CNS) tumors (n = 19; 10%), and (5) “other” SMNs (n = 28; 15%). In 37 patients (20%) preexisting disorders were reported with 90% having any kind of cancer predisposition syndrome (CPS). For the 189 primary NHL patients, 5-year overall survival (OS) after diagnosis of an SMN was 56 ± 4%, being worst for patients with preexisting disorders at 28 ± 8%. Five-year OS rates were 38 ± 8%, 59 ± 7%, 79 ± 8%, 34 ± 12%, and 62 ± 11%, respectively, for patients with myeloid and lymphoid neoplasms, carcinomas, CNS tumors, and “other” SMNs (p < 0.0001). Patients with SMNs after childhood NHL having a reported CPS, mostly mismatch repair disorders, carried a very poor prognosis. Moreover, although outcome was favorable in some subtypes of SMNs after childhood NHL (carcinomas, lymphoid neoplasms), other SMNs such as myeloid neoplasms and CNS tumors had a dismal prognosis.-
dc.languageeng-
dc.publisherSpringer Nature [academic journals on nature.com]. The Journal's web site is located at http://www.nature.com/leu-
dc.relation.ispartofLeukemia-
dc.titleSecond malignant neoplasms after treatment of non-Hodgkin’s lymphoma—a retrospective multinational study of 189 children and adolescents-
dc.typeArticle-
dc.identifier.emailChiang, AKS: chiangak@hku.hk-
dc.identifier.authorityChiang, AKS=rp00403-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/s41375-020-0841-x-
dc.identifier.pmid32393843-
dc.identifier.scopuseid_2-s2.0-85084465559-
dc.identifier.hkuros317473-
dc.identifier.volume35-
dc.identifier.issue2-
dc.identifier.spage534-
dc.identifier.epage549-
dc.identifier.isiWOS:000531783100002-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0887-6924-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats